ClinicalTrials.gg
Active, not recruitingNCT04364555Updated Dec 4, 2024

Efficacy of Topical Treatment With Clobetasol in Symptomatic Oral Lichen Planus.

A Phase 2/3 interventional study of Clobetasol Propionate and Placebo/Klobetasol APL oral gel 0.025% in Oral Lichen Planus, sponsored by Malmö University. Active, not recruiting at 2 sites in Sweden. Open to participants aged 40 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2024-12-04.

Sponsored by Malmö University · Phase 2/3, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2/3
Study type
Interventional
Enrollment
90
Allocation
Randomized
Ages
40 Years and older
Sex
All
01

Study summary

The investigators want to study the effect of clobetasol in symptomatic oral lichen planus. The investigators will include 90 patients and randomly allocate them in three groups. The first group will receive active treatment both in the morning an evening. Group two receives placebo in the morning and active treatment in the evening. Group three will get placebo both in the morning and in the evening. All Groups will follow the same protocol with rinsing twice daily with test substance in conjunction with antifungal treatment. The patients will be controlled after two weeks and and again after another two weeks. A biopsy will be performed at inclusion and another biopsy will be taken at the end of the test period. Smears for candida will also be evaluated. The patients will be examined for changes in clinical appearance and will answer questions to note changes in symptoms. Our hypotheses: #Patients receiving clobetasol will have a better resolution af symptoms than those who got placebo. #Patients treated with clobetasol twice daily will have a faster relief of symptoms than patients just treated once daily. #The clinical signs of oral lichen planus will diminish more pronounced in the two groups given active treatment. #A majority of the OLP lesions were infected by candida. #Specific histological changes can be seen in the biopsies taken after clobetasol treatment compared to those taken before treatment.

02

Conditions studied

  • Oral Lichen Planus

Browse trials for

Keywords

  • Oral lichen planus
  • Treatment
  • Candida
03

In context

Lichen Planus, Oral

143 studies on the registry are indexed under Lichen Planus, Oral; 28 are open to participants now.

This study's planned enrollment of 90 is above the median of 40 across 102 interventional studies indexed under Lichen Planus, Oral.

Browse Lichen Planus, Oral studies →

Lead sponsor

Malmö University is the lead sponsor of 44 studies on the registry; 17 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
40 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Symptomatic oral lichen planus
  • Age above 40 years

Exclusion criteria

Exclusion Criteria:

  • Lichenoid contact lesions
  • Bacteria related lichenoid reaction
  • Intraoral vesiculobullous diseases
  • Active antibiotic treatment
  • Active treatment with or other immunomodulating substance
  • Allergy to Clobetasol
  • Severe periodontitis
  • Bad oral hygiene
  • not supporting OLP
  • Allergy to nystatin
  • Not in menopause
  • Previous or actual oral
  • Participation in other medical study
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

GVHD (graft-versus-host disease)

After a transplant from a donor, the donor’s immune cells attack the recipient’s body, often the skin, gut or liver.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Phase 2 / Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
90 participants (estimated)

Study arms

  • Active comparator
    Active/active

    The one bottle for use in the morning has clobetasol-oral gel, and so does the bottle fore use in the evening. The oral cavity will be rinsed with 5ml oral gel during 1 minute. Nystatin will be taken 1ml 4 times daily.

    Drug: Clobetasol Propionate

  • Active comparator
    Placebo/active

    The bottle for use in the morning contains placebo and one for use in the evening contains clobetasol oral gel. The oral cavity will be rinsed with 5ml oral gel during 1 minute. Nystatin will be taken 1ml 4 times daily.

    Drug: Placebo/Klobetasol APL oral gel 0.025%

  • Placebo comparator
    Placebo/placebo

    Both bottles, the one for the morning and the one for use in the evening, contains placebo. The oral cavity will be rinsed with 5ml oral gel during 1 minute. Nystatin will be taken 1ml 4 times daily.

    Drug: Placebo

Interventions

  • DrugClobetasolStudies of ClobetasolClobetasol pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Klobetasol APL oral gel 0.025% is a topical steroid for rinsing the oral cavity. Manufactured by APL, Sweden.

    Also known as: Klobetasol APL oral gel 0.025%

  • DrugPlacebo/Klobetasol APL oral gel 0.025%

    Placebo/active

  • DrugPlacebo

    Placebo/placebo

06

What researchers measure

Primary outcomes

  1. Clinical appearance of the lichen lesion

    Site-, severity- and activity-score according to Escudier et al

    Time frame: Four weeks

Secondary outcomes

  1. Oral health impact profile

    Oral health impact profile (OHIP-14)

    Time frame: Four weeks

  2. Pain score

    VAS scale. A 10 cm scale ranging from no pain what so ever to worst pain imaginable.

    Time frame: Four weeks

  3. Burning sensation score

    VAS scale. A 10 cm scale ranging from no burning sensation what so ever to worst burning sensation imaginable.

    Time frame: Four weeks

  4. Histological appearance

    Amount and degree of lichenoid reaction in biopsy

    Time frame: Four weeks

  5. Candida

    Candida hyphae in smear from lichen lesions

    Time frame: baseline (At treatment start)

07

Study locations

2 sites
  • Oral surgery, Universityhospital of Scania
    Lund, 22242, Sweden
  • Oral Surgery and oral medicine, Malmö University
    Malmö, 20506, Sweden
08

References and documents

Individual participant data

Plan to share: No — Still undecided since we dont know what data to share and how, yet.

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from May 2020 to primary completion in Jul 2024, 49 months.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 24, 2020
First posted
Apr 28, 2020
StartActual
May 18, 2020
Primary completionActual
Jul 3, 2024
CompletionEst.
Dec 2025
Last update
Dec 4, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 4, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04364555
Lead sponsor
Malmö University
Collaborators
Skane University Hospital, University of Copenhagen
Responsible party
Fredrik Gränse (Dentist, Malmö University) — Principal investigator
First posted
Apr 28, 2020
Start date
May 18, 2020
Primary completion
Jul 3, 2024
Completion
Dec 2025 (estimated)
Last update
Dec 4, 2024

Study contacts

Bengt Götrick, Docent
study chair · Malmö University

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Nov 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Clobetasol

Start the discussion